| Value | ₹20.05 Cr |
|---|
NSE filing, NSE: SAREGAMA. Summary written from the filing by ALFA Finder's alert engine.
Saregama India Ltd: key numbers
- Share price
- ₹636.80
- Market cap
- ₹12,278 Cr
- Revenue (annual)
- ₹984.6 Cr
- Net profit (annual)
- ₹207.1 Cr
- P/E (TTM)
- 50.8×Sector 28.8×
- Promoter holding
- 60.84%+0.00% QoQ
- FII holding
- 11.88%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Saregama India Ltd
All →Saregama India Merger & Restructuring
Saregama India's board approved closing its wholly owned Dubai subsidiary, Saregama FZE, which has no ongoing operations. The closure is not expected to materially affect business operations.
Saregama India Earnings Call Transcript: Key Takeaways
Q2 revenue ₹314 Cr (+37%) and adj. EBITDA ₹118 Cr (+39%), helped by a low base and upfront recognition of old-film licensing. Management pushes a rolling-12-month view.
- Call
- Guides 20% growth
Saregama India Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 3,143 Mn (+37% YoY), Adj. EBITDA INR 1,180 Mn (+39%), PAT INR 642 Mn (+47%). Music-led growth; Live Events doubled; Video down 16%.
Saregama India Q2 FY27 Results: Net Profit ₹64.2 Cr, Up 46.6% YoY
Saregama India Ltd reported revenue from operations of ₹314.3 Cr (+36.7% YoY) and net profit of ₹64.2 Cr (+46.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹64.2 Cr · +46.6% YoY
Saregama India Other Announcement
Saregama India Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure reports the current stake distribution among its shareholders.
Saregama India Employee Stock Options
Saregama India approved the grant of 10,50,000 employee stock options to an eligible employee at an exercise price of Rs. 496.70 per share.
Other merger & restructuring announcements
All →Narayana Hrudayalaya Merger & Restructuring
Narayana Hrudayalaya's NCLT Bengaluru bench sanctioned the demerger of clinical services from its subsidiary NH Integrated Care. Order uploaded today; effectiveness awaits certified copy filings.
Abans Enterprises Merger & Restructuring
Abans Enterprises' board approved voluntary liquidation of wholly owned subsidiary AGJT, subject to shareholder approval. Completion is expected within one year.
- Execution
- Expected within one year, subject to approvals and statutory formalities
Max Estates Merger & Restructuring Worth ₹0.01 Cr
Max Estates will subscribe to 10,000 shares worth ₹1 lakh in a yet-to-be-incorporated real estate company. The entity awaits Ministry of Corporate Affairs approval.
- Value
- ₹0.01 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Choice International Merger & Restructuring Worth ₹1.27 Cr
Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.
- Value
- ₹1.27 Cr
Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr
Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.
- Value
- ₹5.00 Cr